Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 20 2024
0mins
Source: Newsfilter
Delisting from Nasdaq: Altamira Therapeutics Ltd. has been notified of its delisting from Nasdaq due to non-compliance with the minimum bid price rule, effective December 20, 2024, after which it will trade on the OTCQB marketplace under the ticker symbol "CYTOF".
Future Plans: The company aims to focus on its RNA delivery technology and ongoing preclinical programs without the pressure of a reverse stock split, as the OTCQB does not impose the same minimum bid price requirements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
